Octreotide: all 128 studies that test it
Page 2 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney DysfunctionCompletedNCT00240045Phase 2/3
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
- Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
- Treatment of Orthostatic Hypotension in Autonomic FailureCompletedNCT00223691Phase 1
- Prader-Willi Syndrome and AppetiteTerminatedNCT00175305Phase 3
- Octreotide Efficacy and Safety in First-line Acromegalic PatientsCompletedNCT00171886Phase 4
- A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity PatientsCompletedNCT00171613Phase 4
- Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.TerminatedNCT00170742Phase 3
- Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer PatientsCompletedNCT00166725Phase 2
- Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
- Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate ObesityCompletedNCT00094146Phase 2
- Pediatric Hypothalamic ObesityCompletedNCT00076362Phase 4
- Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal CancerCompletedNCT00075868Phase 3
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
- Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
- STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced DiarrheaCompletedNCT00050635Phase 4
- Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the PelvisCompletedNCT00033605Phase 3
- Octreotide and Doxorubicin in Treating Patients With Advanced CancerCompletedNCT00008073Phase 1
- Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon CancerTerminatedNCT00006269Phase 3
- Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by SurgeryCompletedNCT00004895Phase 2
- Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile EctasiaCompletedNCT00004327Phase 2
- Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent ThymomaCompletedNCT00003283Phase 2
- Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal CancerCompletedNCT00003057Phase 3
- Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00002864Phase 3
- Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaCompletedNCT00002779Phase 2
- A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.CompletedNCT00002253Not applicable
- A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related DiarrheaCompletedNCT00002252Not applicable
- A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With OsteosarcomaCompletedNCT00001436Phase 1